A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma

Brief description of study

The purpose of this research study is to test whether Lutathera® (177Lu-DOTATATE) is effective (how well something works) at stopping the growth of meningiomas. This study will also test whether Lutathera® causes any side effects in patients with meningioma. “Investigational” means that the drug is not approved by the US Food and Drug Administration (FDA) for clinical (patient) use for a specific disease, but can be studied in a clinical trial like this one. Lutathera® (177Lu-DOTATATE) has been approved by the FDA for the treatment of a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. These include neuroendocrine tumors in the foregut, midgut, and hindgut in adults.


Clinical Study Identifier: s18-00719
ClinicalTrials.gov Identifier: NCT03971461
Principal Investigator: Erik P. Sulman.
Other Investigators: Minerva A Utate, Maria Del Pilar Guillermo Prieto Eibl, Sylvia Amor Tenefrancia Crispino, Kent P Friedman.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.